Transformative era for medical devices in Asia-Pacific region
APACMed has formed partnerships in the region, but also with MedTech Innovator based in the United States for screening startups in the Asia Pacific region. This reflects 40% of APACmed members being multinational MedTech companies. However 50% of APACMed members are startups from the region itself.
The Asia Pacific MedTech market is forecasted to become the 2nd largest in the world, yet has varying levels of maturity across a diverse number of countries. The region also has large numbers of the ageing population, but spends less than 5% on average in healthcare, for a region where the main disease states are in cardiovascular, orthpedics and diabetes.
Technology to reach global health equity
Dr Terry Knapp, MD as a plastic and reconstructive plastic surgeon, has given back to medicine and global health through over 35 overseas trips as a volunteer surgeon. He is also an inventor with 16 medical device and technology patents to his name. His entrepreneurial spirit has led to founding 6 successful companies, leading to today being the Founder and Chief Medical Officer of CareSpan Health.
Health equity, in technology driven health care delivery, is determined by access to the clinician, specifically communications medical technology. CareSpan Health developed an integrated digital care ecosystem. The architecture of which became, Clinic in the Cloud.
Closing gaps in emergency surgical care
Dr Lynette Scherer In conversation with Mike Lesner talks about trauma being the leading cause of death for under 40 year olds in the US, giving rise to the need to deliver trauma care earlier and more efficiently.
As a trauma surgeon and CEO of Surgical Affiliates Management Group, Inc (or known as SAMGI), Dr Scherer’s organisation addresses variations and gaps in emergency surgical care. The work has led to improvements in care, financial performance of hospitals and clinician satisfaction levels.
New global network into Pulmonary Research
Pulmonary fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred. The debilitating and fatal disease ended the life of an Australian man 8 years ago.
His son led philanthropic efforts to establish the connection between 2 Australian organisations; Lung Foundation Australia and Centre for Research Excellence in Pulmonary Fibrosis and the US based, Three Lakes Foundation. The three organisations recently announced a collaboration to create a global network for PF research.
Clinical research and trials in Australia and New Zealand
Clinical research and trials in the Australia and New Zealand region offer foreign companies an opportunity to collaborate with local institutions, tap into diverse patient populations, access high-quality healthcare infrastructure, and gain regulatory approvals, enabling them to expand their market reach and accelerate the development of innovative medical interventions.
Clinical trials continued in Australia and New Zealand during lockdown, thanks to collaboration between industry and government, allowing the region to attract trials from other countries.
Australia’s digital health push into new national markets
Infection rates following surgical procedure vary across countries, however the causes and the ranges of variation are not well understood.
The causes of the infections are not as high as would be assumed on the surgical procedure, but co-morbidity and lifestyle choices including alcohol consumption may exacerbate risk. As Dr Edmiston states, there are a myriad of causes, and funding is limited in many countries. However there are some solutions, where goals, performance tracking against the goals and better communication is needed.